Pulmatrix, Inc.PULM

Pulmatrix, Inc. still hasn’t turned its inhaled-therapy pipeline into cash: the company’s 10-Q for the quarter ended 31 March 2026 reports a net loss of $1.2 million, an operating loss of $1.3 million, and a quarterly cash burn of $1.1 million from operating activities. Diluted EPS came in at minus 32 cents on 3.7 million weighted shares, while the balance sheet showed $3.3 million in cash and $4.5 million in total assets against $905,000 of liabilities, leaving $3.6 million of shareholders’ equity. The filing quietly notes that none of this yet includes any material product revenue, and that clinical trials may not finish on schedule.

What Pulmatrix actually does is develop novel inhaled therapeutics using proprietary engineered dry-powder delivery systems, as explained on the company’s pipeline page. The filing trail shows the business has been as busy with corporate filing trail as with inhalers: a Master Services Agreement with MannKind from May 2024, a General Release and Severance Agreement with Teofilo Raad from July 2024, and a failed merger sequence that required Chinese regulatory approval before collapsing in February 2026. The research line item in the latest 10-Q is stark-just $3,000 spent on R&D-raising the question of whether the company is frugal or stalled.

The numbers are what they are: negative operating income, negative cash from operations, and a balance sheet that is small but not yet liquidity-constrained. Assets total $4.5 million, with $3.3 million in cash and equivalents, while liabilities sit at $905,000, leaving $3.6 million in equity. Diluted weighted average shares outstanding were 3.7 million, and the company reported a net loss of $1.2 million, equating to a 32-cent diluted loss per share. The filing period covered 31 March 2026, and the same document warns that clinical trials may not complete on schedule. The company’s website hosts the pipeline page and a product image link, but neither turns into revenue in the filings.

For a market view, the company’s SEC filings are the primary rail, with the 10-Q (31 March 2026), 10-K/A (16 June 2026), S-4 (9 July 2026), and 8-K (15 May 2026) providing the latest operating and governance details. The company’s investor-relations site hosts the pipeline page and image assets referenced in the filings, but it does not substitute for audited financial statements or trial outcomes.

What changed recently is mostly on the corporate side. In May 2026 the company reported first‑quarter 2026 financial results and disclosed the collapse of its planned merger with Cullgen after the China Securities Regulatory Commission declined to approve the tie-up. The same month the company announced the closure of a private placement of preferred stock, adding dilution to the narrative. The S‑4 filed in July 2026 reminds investors that other marketing and sales resources may compete for licenses or acquisitions of Pulmatrix’s candidates, and that future clinical trials may slip versus schedule. These are governance and execution items, not product launches, and they shape the near‑term risk set rather than the revenue outlook.

What remains unproven is whether any of the inhaled product candidates will reach approval and, critically, commercial scale. The filings do not yet include material product revenue, and the absence of a clear revenue driver leaves the business reliant on financing and clinical outcomes. The company’s R&D spend in the latest quarter was $3,000, a figure that is either efficient or disconcerting depending on how you read the pipeline progress. Until a product is approved and launched, Pulmatrix’s story will remain a balance-sheet narrative rather than a revenue story.